Kristina Lindemann

  • Head of research, Associate Professor; PhD, MD
  • +47 22 93 49 83

Short bio

Associate professor Kristina Lindemann is a staff specialist at the Department of gynaecologic cancer and head of research group for gynecological oncology. She also leads the National advisory unit of gynaecologic cancer at Oslo University Hospital and is a permanent member of the NSGO-CTU Scientific Committee.

She attended medical school at the University of Heidelberg and München, and worked in the research group of Prof Nadia Harbeck where she received her doctoral degree in 2003. She completed her OB/GYN training the Akershus University Hospital in Oslo and defended her PhD on "Obesity and the risk of endometrial cancer” in 2010. The Global Clinical Scholars Research Training Program at Harvard Medical School added to her research training with focus on clinical trial conduction. Between 2015 and 2016 she worked as a fellow at the Crown Princess Mary Cancer Centre, Westmead, and the NHMRC Clinical Trials Centre in Sydney. Her research focus is to improve patient care in gynaecological cancers, through advancing and translating knowledge in cancer biology, drug development and supportive care.

Kristina Lindemann is higly active in in clinical trials in gynaecologic cancers and has been in involved in the conduct of >20 Phase I-III investigator-initiated and collaborative trials. In 2019 she is Principal Investigator for 9 phase II-III trials, in some of them as National/Nordic coordinator.

She has attracted competitive external funding from the Sister Institution Fund in collaboration with MD Andersen, the ANZGOG New Research Fund and from the Norwegian DAM foundation.

Kristina Lindemann has been awarded outstanding research (Akershus University Hospital, 2011; Oncological Forum, 2011; ASGO 2016) and received an ASCO merit award in 2018. Another important focus of her work is the education of younger colleagues. At Westmead Hospital she developed an online masterclass program for oncological fellows and as previous member of the executive group of the European Network of Young Gynae-Oncologists (ENYGO) she has initiated the LiFE project, a summary of research papers for gynae-onc fellows. She is co-author of the IGCS palliative care curriculum for palliative care.

 

 

Publications 2019

Lindemann K, Zalewski K, Halaska MJ (2019)
Summary of landmark papers published between August 2018 and May 2019
Int. J. Gynecol. Cancer, 29 1, 1-5

Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K (2019)
Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
Int J Gynecol Cancer, 29 (1), 181-187
DOI 10.1136/ijgc-2018-000021, PubMed 30640702

Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L (2019)
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
Cochrane Database Syst Rev (10), CD012160
DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998

Publications 2018

Lindemann K (2018)
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 28 4, 29

Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D, For ANZGOG and HCRN Collaborative Groups (2018)
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Cancer Chemother Pharmacol, 83 (1), 97-105
DOI 10.1007/s00280-018-3706-5, PubMed 30368585

Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A (2018)
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
Gynecol Oncol, 150 (2), 239-246
DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697

Lindemann K, Zalewski K, Halaska MJ, Lindquist D (2018)
PREFACE
Int. J. Gynecol. Cancer, 28 4, 2

Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455

Publications 2017

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
DOI 10.1038/bjc.2016.435, PubMed 28118323

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A (2017)
Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
Int J Gynecol Cancer, 27 (6), 1274-1282
DOI 10.1097/IGC.0000000000000981, PubMed 28498237

Lindemann K, Kok PS, Stockler M, Sykes P, Brand A (2017)
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
Int J Gynecol Cancer, 27 (5), 1046-1050
DOI 10.1097/IGC.0000000000000982, PubMed 28525497

Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K, Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Rebollo JMC, du Bois A, Fotopoulou C (2017)
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
Ann Surg Oncol, 24 (9), 2720-2726
DOI 10.1245/s10434-017-5919-y, PubMed 28608122

Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
Acta Oncol, 56 (10), 1302-1309
DOI 10.1080/0284186X.2017.1330554, PubMed 28548875

Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro Oncol, 19 (7), 976-985
DOI 10.1093/neuonc/now272, PubMed 28040713

Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau E, Lindquist D, Polterauer S, Sukhin V, Dursun P (2017)
A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
Int J Gynecol Cancer, 27 (3), 620-626
DOI 10.1097/IGC.0000000000000917, PubMed 28187096

Publications 2016

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A (2016)
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
Gynecol Oncol, 142 (3), 458-64
DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035

Lindemann K (2016)
Medical treatment of primary or recurrent cervical cancer
Int. J. Gynecol. Cancer, 26 1, 42-43

Lindemann K, Halaska MJ, Zalewski K (2016)
Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
Int. J. Gynecol. Cancer, 26 1, 5-8

Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Ann Oncol, 27 (8), 1505-10
DOI 10.1093/annonc/mdw238, PubMed 27407100

Lindemann K, Zalewski K, Halaska MJ, LiFE Team (2016)
Preface
Int. J. Gynecol. Cancer, 26 1, 2

Lindemann K, Zalewski K, Halaska MJ, Lindquist D, The LiFE Team (2016)
Life - Literature for ENYGO
Int. J. Gynecol. Cancer, 26 4, 2-73

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577

Zalewski K, Lindemann K, Halaska MJ (2016)
Medical treatment of primary ovarian cancer
Int. J. Gynecol. Cancer, 26 1, 9-11

Publications 2015

Lindemann K, Cvancarova M, Eskild A (2015)
Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
Gynecol Oncol, 139 (3), 476-80
DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365

Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2015)
Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
Eur J Epidemiol, 31 (1), 95-8
DOI 10.1007/s10654-015-0033-6, PubMed 25903163

Publications 2014

Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BMC Cancer, 14, 68
DOI 10.1186/1471-2407-14-68, PubMed 24498853

Publications 2013

Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
Long-term outcomes after pelvic radiation for early-stage endometrial cancer
J Clin Oncol, 31 (31), 3951-6
DOI 10.1200/JCO.2013.48.8023, PubMed 24019546

Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2013)
Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study)
Br J Cancer, 109 (1), 289-94
DOI 10.1038/bjc.2013.304, PubMed 23778522

Publications 2012

Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB (2012)
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-9
DOI 10.1093/annonc/mds060, PubMed 22539562

Publications 2011

Rettinger G, Lindemann K, Ashoor M, Scheithauer M, Sommer F, Lindemann J (2011)
[Long term results of transseptal suture of the middle turbinate during sinus surgery]
Laryngorhinootologie, 90 (8), 471-5
DOI 10.1055/s-0031-1280840, PubMed 21809231

Publications 2010

Lindemann K, Eskild A, Vatten LJ, Bray F (2010)
Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027
Int J Cancer, 127 (11), 2661-8
DOI 10.1002/ijc.25267, PubMed 20162667

Publications 2009

Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A (2009)
Serum lipids and endometrial cancer risk: results from the HUNT-II study
Int J Cancer, 124 (12), 2938-41
DOI 10.1002/ijc.24285, PubMed 19267407

Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A (2009)
The impact of BMI on subgroups of uterine cancer
Br J Cancer, 101 (3), 534-6
DOI 10.1038/sj.bjc.6605158, PubMed 19568239

Publications 2008

Lindemann K, Harbeck N, Lengyel E, Resau JH (2008)
A special key for unlocking the door to targeted therapies of breast cancer
ScientificWorldJournal, 8, 905-8
DOI 10.1100/tsw.2008.110, PubMed 18836657

Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A (2008)
Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study
Br J Cancer, 98 (9), 1582-5
DOI 10.1038/sj.bjc.6604313, PubMed 18362938

Publications 2007

Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N (2007)
Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue
Histopathology, 51 (1), 54-62
DOI 10.1111/j.1365-2559.2007.02732.x, PubMed 17593080

Publications 2005

Janni W, Rack B, Lindemann K, Harbeck N (2005)
Detection of micrometastatic disease in bone marrow: is it ready for prime time?
Oncologist, 10 (7), 480-92
DOI 10.1634/theoncologist.10-7-480, PubMed 16079315

Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N (2005)
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
Int J Cancer, 113 (4), 678-82
DOI 10.1002/ijc.20598, PubMed 15455388

Page visits: 991